Endocyte Inc (ECYT)

2.63
NASDAQ : Health Care
Prev Close 2.65
Day Low/High 2.62 / 2.70
52 Wk Low/High 2.55 / 4.47
Avg Volume 174.00K
Exchange NASDAQ
Shares Outstanding 42.27M
Market Cap 112.01M
EPS -1.00
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Endocyte Presents Data On Two Lead Clinical Programs At European Society For Medical Oncology (ESMO) 2016 Congress

Endocyte Presents Data On Two Lead Clinical Programs At European Society For Medical Oncology (ESMO) 2016 Congress

Anti-tumor activity demonstrated in dose escalation trials for EC1456 and EC1169

Noteworthy Wednesday Option Activity: ECYT, GNRC, UVE

Noteworthy Wednesday Option Activity: ECYT, GNRC, UVE

Looking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in Endocyte Inc , where a total volume of 785 contracts has been traded thus far today, a contract volume which is representative of approximately 78,500 underlying shares (given that every 1 contract represents 100 underlying shares). That number works out to 48.1% of ECYT's average daily trading volume over the past month, of 163,335 shares.

A Small Biotech Sells for Less Than Cash

And yet, Endocyte has a deep pipeline.

Endocyte Announces Final Overall Survival Results From Phase 2b TARGET Trial In Non-Small Cell Lung Cancer Patients

Endocyte Announces Final Overall Survival Results From Phase 2b TARGET Trial In Non-Small Cell Lung Cancer Patients

Supports Folate Receptor (FR) as a Valid Target in Non-Small Cell Lung Cancer (NSCLC)